Contact
searchSearch
HMP Global

Drug Recalls

The Latest

News
Lidocaine Hydrochloride Injection Recalled Due to the Presence of Particulate Matter
07/30/2026
Rebecca Amrick
A voluntary Class II recall has been issued for over 180 000 vials of lidocaine hydrochloride injections after particulate matter was identified in the product.
A voluntary Class II recall has been issued for over 180 000 vials of lidocaine hydrochloride injections after particulate matter was identified in the product.
A voluntary Class II recall has...
07/30/2026
Pharmacy Learning Network
News
Glycopyrrolate Injection Recalled Due to the Presence of Particulate Matter
07/30/2026
Rebecca Amrick
Glycopyrrolate injections are under a voluntary Class II recall after particulate matter was identified in the product, prompting pharmacies to remove the affected product from inventory and secure alternative supplies.
Glycopyrrolate injections are under a voluntary Class II recall after particulate matter was identified in the product, prompting pharmacies to remove the affected product from inventory and secure alternative supplies.
Glycopyrrolate injections are...
07/30/2026
Pharmacy Learning Network
News
Amlodipine and Olmesartan Medoxomil Tablets Recalled Due to Failed Dissolution Specifications
07/30/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for amlodipine and olmesartan medoxomil tablets due to failed dissolution specifications.
The US Food and Drug Administration (FDA) has issued a Class II recall for amlodipine and olmesartan medoxomil tablets due to failed dissolution specifications.
The US Food and Drug...
07/30/2026
Pharmacy Learning Network
News
CareOne Carbamide Peroxide Recalled Due to Subpotent Drug
07/23/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for CareOne carbamide peroxide due to the drug’s subpotency, affecting 1201 units.
The US Food and Drug Administration (FDA) has issued a Class II recall for CareOne carbamide peroxide due to the drug’s subpotency, affecting 1201 units.
The US Food and Drug...
07/23/2026
Pharmacy Learning Network
News
Cleviprex Recalled Due to Lack of Sterility Assurance
07/23/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for Cleviprex (clevidipine injectable emulsion) due to a lack of assurance of sterility, affecting 44 280 vials.
The US Food and Drug Administration (FDA) has issued a Class II recall for Cleviprex (clevidipine injectable emulsion) due to a lack of assurance of sterility, affecting 44 280 vials.
The US Food and Drug...
07/23/2026
Pharmacy Learning Network
News
Nystatin Cream Recalled Due to Subpotent Drug
07/23/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for nystatin cream due to the product’s subpotency, affecting 180 936 tubes.
The US Food and Drug Administration (FDA) has issued a Class II recall for nystatin cream due to the product’s subpotency, affecting 180 936 tubes.
The US Food and Drug...
07/23/2026
Pharmacy Learning Network
News
Clomiphene Citrate Recalled Due to CGMP Deviations
07/16/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for clomiphene citrate due to Current Good Manufacturing Practice (CGMP) deviations.
The US Food and Drug Administration (FDA) has issued a Class II recall for clomiphene citrate due to Current Good Manufacturing Practice (CGMP) deviations.
The US Food and Drug...
07/16/2026
Pharmacy Learning Network
News
Bortezomib Injections Recalled Due to Lack of Sterility Assurance
07/16/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for bortezomib injections due to a lack of sterility assurance, affecting 11 400 vials.
The US Food and Drug Administration (FDA) has issued a Class II recall for bortezomib injections due to a lack of sterility assurance, affecting 11 400 vials.
The US Food and Drug...
07/16/2026
Pharmacy Learning Network
News
Methohexital Sodium Injections Recalled Due to Failed Impurities/Degradation Specifications
07/16/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for methohexital sodium injections due to the product’s failure to meet impurities/degradation specifications, affecting 4284 vials.
The US Food and Drug Administration (FDA) has issued a Class II recall for methohexital sodium injections due to the product’s failure to meet impurities/degradation specifications, affecting 4284 vials.
The US Food and Drug...
07/16/2026
Pharmacy Learning Network
News
ADHD Medication Recalled Due to Incorrect Labeling
07/09/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for combination extended-release capsules of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate due to a...
The US Food and Drug Administration (FDA) has issued a Class II recall for combination extended-release capsules of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate due to a...
The US Food and Drug...
07/09/2026
Pharmacy Learning Network
News
Synjardy XR Tablets Recalled Due to CGMP Deviations
07/09/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for Synjardy XR (empagliflozin and metformin hydrochloride) tablets due to Current Good Manufacturing Practice (CGMP) deviations, affecting 560 bottles.
The US Food and Drug Administration (FDA) has issued a Class II recall for Synjardy XR (empagliflozin and metformin hydrochloride) tablets due to Current Good Manufacturing Practice (CGMP) deviations, affecting 560 bottles.
The US Food and Drug...
07/09/2026
Pharmacy Learning Network

Newsfeed

News
Lidocaine Hydrochloride Injection Recalled Due to the Presence of Particulate Matter
07/30/2026
Rebecca Amrick
A voluntary Class II recall has been issued for over 180 000 vials of lidocaine hydrochloride injections after particulate matter was identified in the product.
A voluntary Class II recall has been issued for over 180 000 vials of lidocaine hydrochloride injections after particulate matter was identified in the product.
A voluntary Class II recall has...
07/30/2026
Pharmacy Learning Network
News
Glycopyrrolate Injection Recalled Due to the Presence of Particulate Matter
07/30/2026
Rebecca Amrick
Glycopyrrolate injections are under a voluntary Class II recall after particulate matter was identified in the product, prompting pharmacies to remove the affected product from inventory and secure alternative supplies.
Glycopyrrolate injections are under a voluntary Class II recall after particulate matter was identified in the product, prompting pharmacies to remove the affected product from inventory and secure alternative supplies.
Glycopyrrolate injections are...
07/30/2026
Pharmacy Learning Network
News
Amlodipine and Olmesartan Medoxomil Tablets Recalled Due to Failed Dissolution Specifications
07/30/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for amlodipine and olmesartan medoxomil tablets due to failed dissolution specifications.
The US Food and Drug Administration (FDA) has issued a Class II recall for amlodipine and olmesartan medoxomil tablets due to failed dissolution specifications.
The US Food and Drug...
07/30/2026
Pharmacy Learning Network
News
CareOne Carbamide Peroxide Recalled Due to Subpotent Drug
07/23/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for CareOne carbamide peroxide due to the drug’s subpotency, affecting 1201 units.
The US Food and Drug Administration (FDA) has issued a Class II recall for CareOne carbamide peroxide due to the drug’s subpotency, affecting 1201 units.
The US Food and Drug...
07/23/2026
Pharmacy Learning Network
News
Cleviprex Recalled Due to Lack of Sterility Assurance
07/23/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for Cleviprex (clevidipine injectable emulsion) due to a lack of assurance of sterility, affecting 44 280 vials.
The US Food and Drug Administration (FDA) has issued a Class II recall for Cleviprex (clevidipine injectable emulsion) due to a lack of assurance of sterility, affecting 44 280 vials.
The US Food and Drug...
07/23/2026
Pharmacy Learning Network
News
Nystatin Cream Recalled Due to Subpotent Drug
07/23/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for nystatin cream due to the product’s subpotency, affecting 180 936 tubes.
The US Food and Drug Administration (FDA) has issued a Class II recall for nystatin cream due to the product’s subpotency, affecting 180 936 tubes.
The US Food and Drug...
07/23/2026
Pharmacy Learning Network
News
Clomiphene Citrate Recalled Due to CGMP Deviations
07/16/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for clomiphene citrate due to Current Good Manufacturing Practice (CGMP) deviations.
The US Food and Drug Administration (FDA) has issued a Class II recall for clomiphene citrate due to Current Good Manufacturing Practice (CGMP) deviations.
The US Food and Drug...
07/16/2026
Pharmacy Learning Network
News
Bortezomib Injections Recalled Due to Lack of Sterility Assurance
07/16/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for bortezomib injections due to a lack of sterility assurance, affecting 11 400 vials.
The US Food and Drug Administration (FDA) has issued a Class II recall for bortezomib injections due to a lack of sterility assurance, affecting 11 400 vials.
The US Food and Drug...
07/16/2026
Pharmacy Learning Network
News
Methohexital Sodium Injections Recalled Due to Failed Impurities/Degradation Specifications
07/16/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for methohexital sodium injections due to the product’s failure to meet impurities/degradation specifications, affecting 4284 vials.
The US Food and Drug Administration (FDA) has issued a Class II recall for methohexital sodium injections due to the product’s failure to meet impurities/degradation specifications, affecting 4284 vials.
The US Food and Drug...
07/16/2026
Pharmacy Learning Network
News
ADHD Medication Recalled Due to Incorrect Labeling
07/09/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for combination extended-release capsules of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate due to a...
The US Food and Drug Administration (FDA) has issued a Class II recall for combination extended-release capsules of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate due to a...
The US Food and Drug...
07/09/2026
Pharmacy Learning Network
News
Lidocaine Hydrochloride Injection Recalled Due to the Presence of Particulate Matter
07/30/2026
Rebecca Amrick
A voluntary Class II recall has been issued for over 180 000 vials of lidocaine hydrochloride injections after particulate matter was identified in the product.
A voluntary Class II recall has been issued for over 180 000 vials of lidocaine hydrochloride injections after particulate matter was identified in the product.
A voluntary Class II recall has...
07/30/2026
Pharmacy Learning Network
News
Glycopyrrolate Injection Recalled Due to the Presence of Particulate Matter
07/30/2026
Rebecca Amrick
Glycopyrrolate injections are under a voluntary Class II recall after particulate matter was identified in the product, prompting pharmacies to remove the affected product from inventory and secure alternative supplies.
Glycopyrrolate injections are under a voluntary Class II recall after particulate matter was identified in the product, prompting pharmacies to remove the affected product from inventory and secure alternative supplies.
Glycopyrrolate injections are...
07/30/2026
Pharmacy Learning Network
News
Amlodipine and Olmesartan Medoxomil Tablets Recalled Due to Failed Dissolution Specifications
07/30/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for amlodipine and olmesartan medoxomil tablets due to failed dissolution specifications.
The US Food and Drug Administration (FDA) has issued a Class II recall for amlodipine and olmesartan medoxomil tablets due to failed dissolution specifications.
The US Food and Drug...
07/30/2026
Pharmacy Learning Network
PharmLaw
EyePoint Pharmaceuticals Agrees to $4.6 Million False Claims Act Settlement
07/29/2026
Grace Taylor, MS, MA
EyePoint Pharmaceuticals has agreed to pay $4.6 million to resolve False Claims Act allegations involving DEXYCU marketing practices, highlighting continued federal scrutiny of pharmaceutical manufacturer programs under the Anti-Kickback...
EyePoint Pharmaceuticals has agreed to pay $4.6 million to resolve False Claims Act allegations involving DEXYCU marketing practices, highlighting continued federal scrutiny of pharmaceutical manufacturer programs under the Anti-Kickback...
EyePoint Pharmaceuticals has...
07/29/2026
Pharmacy Learning Network
News
CareOne Carbamide Peroxide Recalled Due to Subpotent Drug
07/23/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for CareOne carbamide peroxide due to the drug’s subpotency, affecting 1201 units.
The US Food and Drug Administration (FDA) has issued a Class II recall for CareOne carbamide peroxide due to the drug’s subpotency, affecting 1201 units.
The US Food and Drug...
07/23/2026
Pharmacy Learning Network
News
Cleviprex Recalled Due to Lack of Sterility Assurance
07/23/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for Cleviprex (clevidipine injectable emulsion) due to a lack of assurance of sterility, affecting 44 280 vials.
The US Food and Drug Administration (FDA) has issued a Class II recall for Cleviprex (clevidipine injectable emulsion) due to a lack of assurance of sterility, affecting 44 280 vials.
The US Food and Drug...
07/23/2026
Pharmacy Learning Network
News
Nystatin Cream Recalled Due to Subpotent Drug
07/23/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for nystatin cream due to the product’s subpotency, affecting 180 936 tubes.
The US Food and Drug Administration (FDA) has issued a Class II recall for nystatin cream due to the product’s subpotency, affecting 180 936 tubes.
The US Food and Drug...
07/23/2026
Pharmacy Learning Network
PharmLaw
Florida Laboratory to Pay $9.8 Million to Resolve FCA Allegations Over Physician Compensation
07/22/2026
Grace Taylor, MS, MA
A Florida laboratory agreed to pay $9.8 million to resolve False Claims Act (FCA) allegations involving physician compensation arrangements that allegedly violated the Stark Law, highlighting ongoing federal scrutiny of referral-based...
A Florida laboratory agreed to pay $9.8 million to resolve False Claims Act (FCA) allegations involving physician compensation arrangements that allegedly violated the Stark Law, highlighting ongoing federal scrutiny of referral-based...
A Florida laboratory agreed to...
07/22/2026
Pharmacy Learning Network
News
Clomiphene Citrate Recalled Due to CGMP Deviations
07/16/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for clomiphene citrate due to Current Good Manufacturing Practice (CGMP) deviations.
The US Food and Drug Administration (FDA) has issued a Class II recall for clomiphene citrate due to Current Good Manufacturing Practice (CGMP) deviations.
The US Food and Drug...
07/16/2026
Pharmacy Learning Network
News
Bortezomib Injections Recalled Due to Lack of Sterility Assurance
07/16/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for bortezomib injections due to a lack of sterility assurance, affecting 11 400 vials.
The US Food and Drug Administration (FDA) has issued a Class II recall for bortezomib injections due to a lack of sterility assurance, affecting 11 400 vials.
The US Food and Drug...
07/16/2026
Pharmacy Learning Network

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use